Market LeadershipManagement is confident in maintaining Voxzogo's market lead in achondroplasia, with new international consensus guidelines recommending early patient identification and treatment with Voxzogo.
Pipeline DevelopmentsAdvancing their internal pipeline with programs like BMN351, BMN333, and BMN390 is a priority for BMRN, indicating a focus on innovation and future growth.
Revenue GrowthBMRN's global presence should support continued revenue growth of Voxzogo and enzyme therapies, with approval in approximately 40 countries and plans to add over 20 new countries.